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Abstract
Background: General practitioners (GPs) and patients find it difficult to talk about risk of future disease, especially
when patients have asymptomatic conditions, and treatment options are unlikely to cause immediate perceptible
improvements in well-being. Further studies in risk communication training are needed. Aim:1) to systematically
develop, describe and evaluate a complex intervention comprising a training programme for GPs in risk
communication and shared decision-making, 2) to evaluate the effect of the training programme on real-life
consultations between GPs and patients with high cholesterol levels, and 3) to evaluate patients’ reactions during
and after the consultations.
Methods/Design: The effect of the complex intervention, based around a training programme, will be evaluated
in a cluster-randomised controlled trial with an intervention group and an active control group with 40 GPs and
280 patients in each group.
The GPs will receive a questionnaire at baseline and after 6 months about attitudes towards risk communication
and cholesterol-reducing medication. After each consultation with a participating high cholesterol-patient, the GPs
will complete a questionnaire about decision satisfaction (Provider Decision Process Assessment Instrument). The
patients will receive a questionnaire at baseline and after 3 and 6 months. It includes questions about adherence
to chosen treatment (Morisky Compliance Scale), self-rated health (SF-12), enablement (Patient Enablement Instru-
ment), and risk communication and decision-making effectiveness (COMRADE Scale). Prescriptions, contacts to the
health services, and cholesterol level will be drawn from the registers.
In each group, 12 consultations will be observed and tape-recorded. The patients from these 24 consultations will
be interviewed immediately after the consultation and re-interviewed after 6 months.
Eight purposefully selected GPs from the intervention group will be interviewed in a focus group 6 months after
participation in the training programme.
The process and context of the RISAP-study will be investigated in detail using an action research approach, in
order to analyse adaptation of the intervention model to the specific context.
Discussion: This study aims at providing GPs and patients with a firm basis for active deliberation about
preventive treatment options, with a view to optimising adherence to chosen treatment.
Trial registration: ClinicalTrials.gov Protocol Registration System NCT01187056
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Background
Much attention has been given to how risk information
should be communicated to patients with established
conditions requiring treatment or specific surveillance
strategies [1-3]. In prevention of disease, however, risk
communication needs further elaboration; especially
where preventive treatments are not likely to cause
immediate perceptible improvements in well-being. This
is a particular problem in the prevention of cardiovascu-
lar disease which is a major cause of morbidity,
impaired quality of life and premature death worldwide.
It has been argued that preventive treatment to lower
the risk of cardiovascular disease is underused as a
result of both general practitioners’ low adherence to
clinical guidelines and patients’ low adherence to pre-
ventive treatment [4-6]. The issue therefore arises as to
whether prevention of cardiovascular disease can be
improved through enhanced communication.
High cholesterol is a well-defined risk factor for cardio-
vascular disease [7,8]. It is asymptomatic and usually
detected by opportunistic screening in primary care. A
change of life style is usually recommended to patients
with high cholesterol. When this does not achieve suffi-
cient reduction in the cholesterol level, cholesterol-
reducing medication is usually suggested. Cholesterol-
reducing medication has been shown to effectively reduce
the risk of fatal heart disease [9]. The risk reduction
depends on continuous (lifelong) medication. However, a
review on prevention of cardiovascular disease has shown
that 50% of all patients prescribed with cholesterol-redu-
cing medication stop treatment within 6 months, with a
further decline after one year. This decline is most pro-
minent in patients with no symptoms of cardiovascular
disease [10,11]. When patients do not comply with pre-
scribed preventive medication for cardiovascular disease,
the benefits will not be fully achieved [12,13].
Non-adherence to preventive medication may be due
inter alia to inadequate knowledge about risk of disease,
uncertainty about treatment benefits, and anxiety about
side-effects [14]. In order for patient-centred care to be
effective, it is important to support initiatives that
ensure sufficient information about risks and benefits
[15,16].
The choice to prioritise preventive treatment over
watchful waiting should be taken collectively by the gen-
eral practitioner (GP) and the individual patient [17].
Such co-operation is often complicated by contradictory
perceptions of risk of disease and dangers associated
with preventive treatment [18]. This is consistent with
sociological and ethnographic studies showing that per-
ceptions and deliberations of risk and danger are con-
text-specific and embedded in knowledge traditions and
complex socio-cultural relationships [19,20].
Shared decision-making (SDM) has been developed to
enhance patient autonomy and engage patients in the
process and responsibility of decision-making [21]. It
includes a key component of risk communication [22].
SDM enhances patient involvement, though its benefits
on patient-based outcomes, such as knowledge, anxiety,
satisfaction and actual choice or adherence to chosen
treatments (including choosing no treatment if relevant)
are less clear [23,24]. SDM can be supported in different
ways. Firstly, patient decision aids have been developed
to facilitate patient-doctor communication about risk.
Patient decision aids assist patients in making informed
value-based choices by providing evidence-based infor-
mation about a health condition, treatment options
(including no-treatment), and potential benefits and
harms, including risk numbers in different formats [25].
Secondly, training of healthcare professionals in shared
decision-making, risk communication, and use of patient
decision aids has been undertaken. Some studies have
shown positive results in terms of patient satisfaction,
patients’ knowledge about risk, healthcare professional/
patient-relationship, and patients’ involvement in the
medical decision [26,27] but this has been inconsistent
in the literature to date [2].
There are a number of gaps in the evidence base.
Training methods and training extent are often poorly
described in published articles [28-30]. Few studies have
determined effects of risk communication and/or deci-
sion aids on adherence to the chosen therapy [2].
Furthermore, only a few observational studies of doctor/
patient risk communication have investigated real-life
consultations [31-36]. Further studies in these areas of
risk communication for disease prevention are needed
as are studies about risk communication training for
GPs and the use of decision aids. These studies need to
develop and evaluate interventions that address a range
of likely difficulties - in training and adoption of SDM
and risk communication skills, use of decision aids with
real patients, and follow-up of their effectiveness as
patients try to adapt treatment plans to their everyday
lives. By nature these are ‘complex interventions’ [37]
and will benefit from multi-faceted evaluation [38].
Objective
The objective of the RISAP study is 1) to systematically
develop, describe and evaluate a complex intervention
comprising a training programme for GPs in risk com-
munication and shared decision-making, 2) to evaluate
the effect of the training programme on real-life consul-
tations between GPs and patients with high cholesterol,
and 3) to evaluate the patients’ reactions during and
after the consultations and adherence to chosen treat-
ment plans.
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RISAP is an acronym for Risk Communication in
General Practice.
The hypotheses are that the intervention group
patients will have higher adherence to chosen treatment,
have better self-rated health and fewer contacts with
health services, have better satisfaction with treatment
decision, and experience no increased anxiety, compared
to the control group patients.
Methods and design
Participants
GPs in Region Central and Region North, Denmark, are
invited to the study.
Patients are at least 18 years old, and have high cho-
lesterol corresponding to a recommendation for choles-
terol-reducing medication according to Danish clinical
guideline for general practice [39]. The patients are
recruited after their high cholesterol has been detected
and when treatment options are to be discussed.
Patients with CVD or DM are excluded from the
study, as are patients already receiving cholesterol-redu-
cing medication and patients unable to speak and read
Danish.
Intervention
The intervention is a training programme for GPs in
risk communication and shared decision-making. It con-
sists of workshop sessions of 2×2 hours’ duration and
includes teacher-led discussions and GP role plays relat-
ing to risk communication, shared decision-making
principles, and primary prevention of cardiovascular dis-
ease in general practice. In addition, the GPs will have
training in the use of visual representations of risk and
risk reduction, as well as a patient decision aid devel-
oped specifically for the training programme (please see
“Development of the intervention” below).
The control group GPs will receive 2 hours of training
in the primary care guideline for prevention of cardio-
vascular disease [39].
In both intervention group and control group, each
workshop session will have 6-10 GPs led by two tea-
chers from the teaching group (JT/BH/TL). The control
group GPs will be invited to receive the full training
programme after the conclusion of the study.
After participation in the workshop sessions, the GPs
will return to their practices. When the GP identifies a
patient with high cholesterol and is likely to suggest pre-
ventive pharmacological treatment, the GP will invite
the patient to participate in the study. If the patient
accepts participation, the GP will use the skills from the
sessions (either intervention or control) during the con-
sultation. Each GP will invite and recruit a minimum of
7 (consecutive) patients. Recruitment will be reimbursed
with a fee of 300 DKK (35 £/40 €) per patient.
The study will be administered by three researchers
and members of the RISAP project group. It will, how-
ever, also be administered by the participating GPs as
they invite patients to the study.
Development of the intervention
A preliminary draft for a training programme in risk
communication and shared decision-making was devel-
oped by academic general practitioners and social scien-
tists in the RISAP project group (PK, JT, MJ, AE, TL,
BH, MR). The draft was based on literature review and
experience from previous studies and entailed sugges-
tions for improving ways to communicate about risk -
including shared decision-making principles, visual
representations of risk and risk reduction, decision sup-
port, and a patient decision aid.
61 GPs in Kolding, Region South, Denmark, were con-
tacted by telephone by PK and BH, asking either the
secretary or the GP permission to send a written invita-
tion to a two-hour focus group interview. The invitations
were sent directly to each of the GPs in the practices,
with a note to return in an enclosed envelope to indicate
willingness to participate (in Sept 2008). Participation
was re-imbursed with a fee of 1400 DKK (165 £/188 €).
30 GPs returned the note, and 10 GPs (six male, four
female) accepted participation on either of the two dates
suggested in the written invitation, and two GPs (two
female) offered participation on a later date. Average age
was 48 years, ranging from 41 to 56 years.
The six GPs in the first focus group interview were
first asked about their experiences with risk communica-
tion and decision-making with patients with high cho-
lesterol. In the second half of the interview, the GPs
were presented with the preliminary draft for the train-
ing programme. They were prompted to express their
thoughts and ideas for further development from the
preliminary draft. After the interview, these experiences,
thoughts and ideas were categorised and interpreted,
and members of the RISAP project group revised the
preliminary draft accordingly. After the revision, the
next two groups of GPs were interviewed, repeating the
process of prompting and draft revision.
The GPs were asked to recruit at least one patient
with high cholesterol deliberating cholesterol-reducing
medication, for an individual interview with a researcher
(PK). Four GPs recruited 12 patients, six male, six
female. They were interviewed individually about their
experiences with living with high cholesterol, treatment
issues and with decision-making and risk communica-
tion with their GP. They were also presented with parts
of the revised draft, i.e. the visual representations of risk
and risk reduction, and the patient decision aid. They
were prompted to express their thoughts and ideas for
further development.
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The data from the patient interviews were categorised
and interpreted after the conclusion of the 12 inter-
views. The visual representations of risk and risk reduc-
tion and the draft decision aid were revised accordingly.
Study Design and Randomisation
The effect of the complex intervention, based around a
training programme for GPs, will be evaluated in a clus-
ter-randomised controlled trial with an intervention
group and an active control group [37,40,41].
Each participating practice will form a ‘cluster’. Prac-
tices will be randomised to participate in either inter-
vention or control group. The randomisation of the GPs
is stratified according to single-handed practice or
group practice, gender (male/female/both sexes) and age
(average age of participating GPs if more than one GP
from a group practice participate), and urban or rural
practice. Randomisation will be undertaken by random
number generation, and allocations by a program made
by an independent statistician will be concealed from
those implementing the intervention. Both GPs and
patients will be informed that the study investigates car-
diovascular risk management but the patients will be
‘blinded’ to which group they are in.
In each group, 12 consultations will be observed and
tape-recorded by a researcher (PK). The consultations
will be divided between 4 GPs, each with 3 patients. The
GPs will be selected according to gender and age (1 male
+ 1 female GP ≥ 48 years, 1 male GP + 1 female GP < 48
years). The patients from these 2×12 consultations will
be interviewed immediately after the consultation and re-
interviewed after 6 months. The interview will be of
approx. 45 minutes duration. The tape-recorded consul-
tation will be played back during the interview with the
patient, using the Think Aloud-method [42,43]. The
observations during the consultation will be written
down as ethnographic field notes [44]. The aim is to
make a rich and detailed ‘thick’ description [45] of the
consultation. The patient interviews after the consulta-
tions will focus on the patients’ immediate reactions to
risk communication and decision-making in the consul-
tation, using a semi-structured interview guide with open
questions and play back of the tape-recorded consulta-
tion. The patients will be re-interviewed after 6 months.
Eight GPs from the intervention group will be inter-
viewed in a focus group 6 months after participation in
the workshop sessions. They will be selected according
to gender and age (2 male + 2 female GP ≥ 48 years, 2
male GP + 2 female GP < 48 years). The purpose of the
focus group interview is to get feedback on the interven-
tion process and the training programme, with a parti-
cular view to examining their assessment of the risk
communication tools developed for the intervention, to
inform future implementation strategies.
The process and context of the RISAP-study will be
investigated in detail using an action research approach
[46-48]. It includes ‘thick’ ethnographic descriptions of
the research process in order to describe and analyse
the continuous critical reflection in the project group on
research choices, adaptation of intervention model to
the specific context, and conscious and pragmatic per-
formance strategies in scientific and political commu-
nities and networks [49-51].
Outcomes
The primary patient outcome is adherence to treatment
choice. Secondary patient outcomes are self-rated health,
anxiety, satisfaction with decision, enablement, satisfac-
tion with communication, satisfaction and confidence in
decision, and number of contacts to health services.
The primary GP outcome is satisfaction with decision.
Secondary GP outcomes are GP attitudes towards risk
communication and towards preventive treatment of
cardiovascular disease, patient involvement in decision-
making, and use of risk communication tools.
Outcome measurement
The patients will receive a questionnaire at baseline and
after 3 and 6 months. It includes questions from vali-
dated scales: the Morisky Compliance Scale is used to
assess adherence to chosen treatment, defined as 80% of
the scheduled treatment taken as prescribed [52-54].
Self-rated health will be measured with questions from
SF-12 [55-64], and patient enablement will be measured
with the Patient Enablement Instrument [65]. Risk com-
munication and decision-making effectiveness will be
measured using the COMRADE scale [66]. In addition,
the questionnaire will include questions on the patients’
socio-demographic circumstances.
Prescriptions, contacts to the health services, and cho-
lesterol level will be drawn from the register of the
National Health Service of Denmark at baseline and at 6
months. The cholesterol level will be measured only on
the GP’s own initiative.
The GPs will receive a questionnaire at baseline and
after 6 months about attitudes towards risk communica-
tion and cholesterol-reducing medication. After each
consultation with a participating high cholesterol-
patient, the GPs will complete a questionnaire about
decision satisfaction with questions from the Provider
Decision Process Assessment Instrument [67]. In addi-
tion, the GP will be asked to identify which, if any, risk
communication tools were used during the consultation.
Sample size
A simulated power calculation shows that a trial with 40
practices in each group (at least 1 GP per practice and
at least 7 patients with high cholesterol per GP) ensures
Kirkegaard et al. BMC Family Practice 2010, 11:70
http://www.biomedcentral.com/1471-2296/11/70
Page 4 of 7
a statistical power of 90% for detecting a 10% difference
in lack of adherence (from 20% to 10%) at a significance
level of 5%. The patients’ adherence rates are assumed
to vary from GP to GP according to a normal distribu-
tion on a logarithmic scale. The variance of the latent
normal distribution is determined by assuming that 95%
of the patients adherence levels within each GP vary
within the intervals 0.08 to 0.50 (active control group)
and 0.04 to 0.25 (experimental group).
Data analysis
Descriptive statistics will be generated for all variables.
All analyses will be intention to treat. Data concerning
adherence will be analysed by multivariate binomial
regression with a latent variable with a level for each
practice. Multivariate logistic regressions models will be
used to determine variables independently associated
with the outcome variable for questionnaire data. Miss-
ing responses will be excluded from the analysis. A
probability level of p < 0.05 based on two-sided tests is
considered statistically significant.
The qualitative research process will be iterative, alter-
nating between data production, analysis, and theory.
Informal analysis has been conducted in the develop-
mental stage of the study and continues in a kind of
funnel structure of “progressive focusing” [51]. The data
from the interviews will be transcribed verbatim, and
these transcriptions and written field notes will undergo
a thematic analysis in which key patterns will be identi-
fied and grouped into themes [68]. The core themes and
their meanings and interrelations will be explored and
interpreted, using appropriate formal theories [69].
Discussion
Preventive treatment is fraught with uncertainty about
the “true state” of health of asymptomatic patients at
risk of becoming seriously ill. Both GPs and patients
find it complicated to talk about the risk numbers and
risk formats that may be a substantial part of the delib-
eration. This study aims at providing GPs and patients
with a firm basis for active deliberation about preventive
treatment options, with a view to optimising adherence
to chosen treatment. The study results will provide a
basis for recommendations about ways to communicate
risk and facilitate shared decision-making during general
practice consultations. The interviews and observations
will allow the researchers in the project group to
describe and support the learning processes during the
training sessions in the complex intervention. This gives
the opportunity to make the content, processes, meth-
ods and challenges as transparent as possible in the
reporting of the results, adding much needed experience
gathering about the possible ‘active ingredients’ of com-
plex interventions in risk communication and shared
decision-making. This will be interpreted to inform
future implementation strategies for similar interven-
tions in primary care.
Ethical aspects
The study will be conducted according to the Helsinki
Declaration. It has been notified to the Danish Data
Protection Agency and collection of data will be handled
according to their guidelines. The study is exempted
from obligation of notification for the Scientific-ethical
committee (pursuant to § 8 [3] of the rules of the com-
mittee) but follows the ethical code of American
Anthropological Association [70]. It has been registered
at ClinicalTrials.gov: NCT01187056.
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